OptiBiotix Health expects revenue boost as it switches from R&D focus

Writer, Stock Market Wire
Wednesday, February 13, 2019 - 07:51

OptiBiotix Health said it had boosted its annual income as it continued to transition from an R&D business to a commercial company generating sales.

Revenue for the year through November had jumped to £541k, up from £191k on-year, with the bulk booked in the second half of the year.

'We anticipate further revenue growth in 2019 as existing deals contribute to full year revenues, and partners continue to grow sales,' the company said.


Related content

OptiBiotix Health inks distribution pact with DKSH in Italy and Spain

OptiBiotix Health said it had entered into an exclusive agreement with DKSH International to distribute its weight management technology in Italy and Spain.

Market exclusivity...

Wed, 20/03/2019 - 07:13


OptiBiotix Health extends supply agreement with HLH BioPharma Vertriebs

OptiBiotix Health said subsidiary ProBiotix Health had extended an original supply agreement with HLH BioPharma Vertriebs.

The agreement covered the supply of the company's cholesterol-reducing...

Fri, 15/03/2019 - 07:46


OptiBiotix Health presents studies on products at Copenhagen conference

OptiBiotix Health said it presented study materials on three products at a key industry conference in Copenhagen.

Three abstracts were presented at the ProBiota 2019...

Wed, 20/02/2019 - 08:25


OptiBiotix Health inks Japan distribution agreement with EIWA Trading

OptiBiotix Health said subsidiary ProBiotix Health had appointed EIWA Trading as the exclusive distributor of its cholesterol and blood pressure-reducing probiotic product in Japan.

The...

Mon, 11/02/2019 - 07:34


OptiBiotix Health inks distribution pact with SilvEXPO for Russia, Kazakhstan

OptiBiotix Health said it had entered into a three-year distribution agreement with SilvEXPO for markets in Russia and Kazakhstan.

The agreement would see SilvExpo distribute...

Wed, 09/01/2019 - 07:54